Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Carboplatin|DRUG: Docetaxel
Sponsor: Cinnagen